Le Lézard
Classified in: Health, Business
Subjects: FNC, VEN

Koya Medical Raises New Capital with OrbiMed to Support Growth


OAKLAND, Calif. and NEW YORK, Nov. 15, 2023 /PRNewswire/ -- OrbiMed, a leading healthcare investment firm and Koya Medical, a healthcare company with a mission to transform venous and lymphatic treatments through novel, people-centric solutions, today announced the closing of a financing for up to $30 million. The capital will support the company's strategic expansion and continued growth.

"We are excited to partner with Koya on its journey to deliver innovative offerings that can help millions of patients living with these chronic conditions," said Matthew Rizzo, General Partner, OrbiMed. "Lymphedema treatments are an underserved area for many patients, and we are just beginning to understand the full impact these diseases have on patients' daily lives. We are pleased to have OrbiMed join us along with our existing investors on this important mission," said Josh Baltzell, Board Chairman, Koya Medical.

With the close of this financing, Koya is well positioned to continue the growth of its Dayspring treatment for lymphedema. "Lymphedema and chronic venous diseases have tremendous unmet needs where millions of patients suffer due to the progressive nature of these conditions and their debilitating impacts. With OrbiMed joining our journey, we will be able to make a stronger impact in improving patient lives," said Andy Doraiswamy, CEO. "This partnership and funding will enhance our abilities to better serve our patients."

About Lymphedema

An estimated 20 million Americans live with lymphedema, a progressive, incurable condition where a buildup of protein rich fluid causes painful swelling in the arm, leg, and/or other regions of the body. For most, lymphedema requires lifelong maintenance and various levels of therapy to control swelling and pain. Lymphedema can result from a variety of factors, including cancer, chronic venous disease, infection, and surgery. 

About Koya Medical

Koya Medical, a privately held company founded in 2018, is a transformative healthcare company developing breakthrough treatments for venous diseases and lymphedema and personalized care that is unavailable with traditional treatments. For company or product inquiry, contact [email protected].
Follow us on LinkedIn at www.linkedin.com/company/koyamedical/.

SOURCE Koya Medical


These press releases may also interest you

at 06:49
"I'm extremely thankful that President Xi spent time to write to us. It was very touching he was able to hear about the amazing times on our trip," Seinna Stonking, a freshman at Muscatine High School in the central US state of Iowa, told the Global...

at 06:43
Shanghai Electric (SEHK:2727, SSE:601727) announced that the Company...

at 05:54
Contributing to the advancement of genomics in Latin America, MGI Tech Co. Ltd. (MGI), a company committed to building core tools and technology to lead life science, announced the launch of its Customer Experience Center (CEC) in Brazil.  ...

27 avr 2024
On April 25, 2024, CATL (SZ:300750) and Beijing Hyundai signed a strategic partnership agreement at Auto China 2024 to cooperate on Beijing Hyundai's EV projects and to power future Beijing Hyundai electric models with CATL batteries....

27 avr 2024
Sola Salons, the world's largest studio suites franchise for more than 20,000 independent beauty professionals, proudly announces the opening of its Southern Oregon location in Medford, Oregon. In 2004, Sola Salons was the first in the industry to...

27 avr 2024
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of bluebird bio, Inc. between April 24, 2023 and December 8, 2023, both dates inclusive (the "Class Period"), of the important May 28, 2024 lead plaintiff...



News published on and distributed by: